Peptide vs Small Molecule — Oncology Deal Terms Comparison
Market Analysis
In oncology, Peptide and Small Molecule represent two of the most actively transacted modalities. At Phase 2, Peptide deals carry a median total deal value of $1.7B with $271M upfront, compared to $1.6B total value and $258M upfront for Small Molecule. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Peptide development milestones average $362M versus $345M for Small Molecule. Commercial milestones are $507M for Peptide and $483M for Small Molecule. Royalty rates range from 12%-19.6% for Peptide and 11.8%-19.3% for Small Molecule.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Peptide and Small Molecule deal terms compare in oncology?
Which modality commands higher royalty rates: Peptide or Small Molecule?
How do milestone structures differ between Peptide and Small Molecule?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.